A Multicenter Phase IIb Randomized, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Document safety profile of 930 μg of L-BLP25.
Day 0, Weeks 1, 2, 3, 4, 5, 6, 7, 8, 13, 19, 25, 31, 37, 43, 49, 55, Month 24. Additional inquires on survival until death.
No
Martin Falk, MD
Study Director
Merck KGaA
Canada: Health Canada
B25-LG-304 / EMR 63325-005
NCT00157209
August 2000
Name | Location |
---|